franco locatelli: Live & Latest News Updates : Vimarsana.com

Italy's healthcare system under threat, experts warn – Euractiv

Vertex Pharmaceuticals - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

LONDON - Vertex Pharmaceuticals Incorporated announced today that the European Commission has granted conditional marketing authorization to CASGEVY , a CRISPR/Cas9 gene-edited therapy. CASGEVY is...

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment - ...

Vertex Pharmaceuticals Incorporated: European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemc

- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment -LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authoriza...

New CRISPR Gene-Editing Treatment Approved In Europe

The decision comes after Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy was approved in the UK and US for sickle cell disease and beta thalassemia.

Vertex secures European approval for CRISPR cell therapy

Presidential Candidate Bobby Kennedy Wins the Coveted Orphan Dream Award

Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

 - If approved by the European Commission, patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia, for whom hematopoietic stem cell...

Vertex Pharmaceuticals Incorporated: Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia